For the second quarter of the fiscal year ending March 2027, revenue was 4,792 million yen, up 9.4% year-over-year. Operating loss was 334 million yen, ordinary loss was 303 million yen, and interim net loss was 181 million yen. Impacts from drug price revisions and cost trends affected results. Segments are Pharmaceuticals, Healthcare, Global, and Real Estate Leasing, with mixed revenue movement across them.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4512","jir_company_name":"Wakamoto Pharmaceutical Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4512-20261106-01.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, revenue was 4,792 million yen, up 9.4% year-over-year. Operating loss was 334 million yen, ordinary loss was 303 million yen, and interim net loss was 181 million yen. Impacts from drug price revisions and cost trends affected results. Segments are Pharmaceuticals, Healthcare, Global, and Real Estate Leasing, with mixed revenue movement across them.","jir_summary":"### Overview of Results\nInterim revenue was 4,792 million yen, an expansion of 9.4% year-over-year. However, the Company recorded an operating loss of 3,334 million yen, an ordinary loss of 3,033 million yen, and an interim net loss of 1,811 million yen. Gross profit was 18,311 million yen, down 8.3% year-over-year. Impacts from drug price revisions and trends in selling, general and administrative expenses were factors suppressing profits. By segment, the Pharmaceuticals and Global segments drove growth while Real Estate Leasing remained stable. Gains on sales of investment securities were recorded as extraordinary profit.\n\n### Financial Position and Outlook\nTotal assets are in the 15.7 billion yen range, and the equity ratio remains high at 73.6%. Changes in the asset composition were observed due to a decrease in cash and deposits, increases in inventories, and partial expansion of the Sagami-Oi factory. For the second half, while considering the effects of drug price revisions during the pollen season and planned production line downtime, improvement in cost of sales ratio is expected under total cost accounting. The Company announced no change to its earnings guidance for the fiscal year ending March 2027.","jir_financial_highlights":"Revenue: 4,792 million yen (Up 9.4% Year-over-Year)\nOperating Loss: -334 million yen (Decrease of -138 million yen Year-over-Year)\nOrdinary Loss: -303 million yen (Decrease of -127 million yen Year-over-Year)\nInterim Net Loss: -181 million yen (Decrease of -47 million yen Year-over-Year)\nEquity Ratio: 73.6% (Up 0.8% from previous fiscal year)","jir_category":"","jir_hashtags":"#WakamotoPharmaceutical, #Earnings, #Interim, #DrugPriceRevisionImpact","jir_key_figures":"Revenue: 4,792 million yen (Up 9.4% Year-over-Year)\nOperating Loss: -334 million yen\nInterim Net Loss: -181 million yen\nEquity Ratio: 73.6%","jir_meta_title":"Wakamoto Pharmaceutical Co.,Ltd. - FY2027 Q2 Interim Financial Summary | Revenue 4.792 billion yen, +9.4%","jir_meta_description":"Wakamoto Pharmaceutical Co.,Ltd. FY2027 Q2 interim Financial Summary. Revenue 4.792 billion yen, operating loss 334 million yen, net loss 181 million yen. Analysis of impacts from drug price revisions and segment trends.","jir_og_title":"Wakamoto Pharmaceutical Co.,Ltd. - FY2027 Q2 Interim Results | Revenue 4.792 billion yen","jir_og_description":"Wakamoto Pharmaceutical Co.,Ltd. interim financial results. Revenue up 9.4% YoY; analysis of factors behind losses and segment performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026\/4-9\\\",\\\"2027\/4-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4792,4792]}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Loss Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026\/4-9\\\",\\\"2027\/4-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Loss\\\",\\\"data\\\":[-195,-334]}]}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Loss Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026\/4-9\\\",\\\"2027\/4-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Loss\\\",\\\"data\\\":[-134,-181]}]}\"}, {\"jir_chart_id\": \"equity_ratio\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026-03-31\\\",\\\"2026-09-30\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[72.8,73.6]}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Healthcare\\\",\\\"Global\\\",\\\"Real Estate Leasing\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2203,1190,896,92.3]}]}\"}, {\"jir_chart_id\": \"seg_profit_loss\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit\/Loss\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Healthcare\\\",\\\"Global\\\",\\\"Real Estate Leasing\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Loss\/Profit\\\",\\\"data\\\":[-445,130,87,33.6]}]}\"}]","ir_related_company":58985,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144030","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n